Impact of Percutaneous Coronary Intervention on Renal Function in Patients with Ischemic Heart Disease
Abstract
Background. Contrast-induced nephropathy (CIN) is a common complication among patients with
ischemic heart disease (IHD) undergoing percutaneous coronary intervention (PCI). Understanding the pathogenesis, risk factors, and preventive measures of CIN is essential for reducing morbidity and mortality.
Materials and methods. An analysis was conducted on patients with IHD who underwent PCI with contrast media administration. Renal function indicators, including serum creatinine levels and glomerular filtration rate, were assessed pre- and post-procedure. Clinical manifestations, CIN incidence, and associated risk factors were evaluated.
Results.The incidence of CIN varied based on baseline renal function and comorbidities. Key risk factors included elevated baseline serum creatinine, diabetes mellitus, and advanced age. Hydration therapy was effective in reducing the incidence of nephropathy.
Conclusion. PCI increases the risk of CIN in IHD patients, particularly in those with predisposing risk factors. Comprehensive renal function assessment and preventive measures are recommended prior to the procedure to minimize risk.
About the Authors
List of references
Avetisov K.S., Fedorov A.A., Novikov I.A., Light and scanning electron microscopy of anterior lens capsule following different capsulorhexis techniques, Vestnik oftal’mologii, 2015, 131, 06, 4– 10, 10.17116/oftalma201513164-10, In Russian: Аветисов К.С., Федоров А.А., Новиков И.А. Световая и сканирующая электронная микроскопия передней капсулы хрусталика после различных методик капсулорексиса. Вестник офтальмологии. 2015;131(6):4-10.
Coyle L.C., Rodriguez A., Jeschke R.E., Acetylcysteine in Diabetes (AID): A randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics, Am Heart J, 2006, 151, 05, 1032.e9–1032.e12, 10.1016/j.ahj.2006.02.002.
Budhiraja P., Chen Z., Popovtzer M., Sodium bicarbonate versus normal saline for protection against contrast nephropathy, Ren Fail, 2009, 31, 02, 118–123, 10.1080/08860220802599239.
Jawdeh B.G., Kanso A., Schelling J.R., Evidence-based approach for prevention of radiocontrast-induced nephropathy, J Hosp Med, 2009, 4, 08, 500–506, 10.1002/jhm.484.
Chong E., Poh K.K., Liang, S., Comparison of risks and clinical predictors of contrast-induced nephropathy in patients undergoing emergency versus nonemergency percutaneous coronary interventions, J Interv Cardiol, 2010, 23, 05, 451–459, 10.1111/j.1540-8183.2010.00573.x.
Alyavi B., Uzokov J., Muminov Sh., Kamilova S., Contrast-induced nephropathy in coronary patients, JACC, 2018, 72, 016, 222.
Detrenis S., Meschi M., Bertolini L., Contrast medium administration in the elderly patient: is advancing age an independent risk factor for contrast nephropathy after angiographic procedures?, J Vasc Interv Radiol, 2007, 18, 02, 177–185, 10.1016/j.jvir.2006.11.020.
Cowburn P.J., Patel H., Pipes R.R., Contrast nephropathy post cardiac resynchronization therapy: an under-recognized complication with important morbidity, Eur J Heart Fail, 2005, 7, 05, 899–903, 10.1016/j.ejheart.2005.01.015.
Kedrah A.E., Ari E., Alahdab Y., Effect of the direct renin inhibitor aliskiren in the prevention of experimental contrast-induced nephropathy in the rat, Kidney Blood Press Res, 2012, 35, 06, 425–430, 10.1159/000338672.
Albabtain M.A., Almasood A., Alshurafah H., Efficacy of ascorbic acid, N-acetylcysteine, or combination of both on top of saline hydration versus saline hydration alone on prevention of contrast-induced nephropathy: a prospective randomized study, J Interv Cardiol, 2013, 26, 01, 90–96, 10.1111/j.1540- 8183.2012.00700.x.
Gami A.S., Garovic V.D., Contrast nephropathy after coronary angiography, Mayo Clin Proc, 2014, 79, 02, 211–219, 10.4065/79.2.211.
Goldenberg I., Matetzky S., Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies, CMAJ, 2005, 172, 011, 1461–1471, 10.1503/cmaj.1041114.
Gomes V.O., Lasevitch R., Lima V.C., Hydration with sodium bicarbonate does not prevent contrast nephropathy: a multicenter clinical trial, Arq Bras Cardiol, 2012, 99, 06, 1129–1134, 10.1590/s0066- 782x2012005000107.
Conen D., Buerkle G., Perruchoud A.P., Hypertension is an independent risk factor for con- trast nephropathy after percutaneous coronary intervention, Int J Cardiol, 2006, 110, 02, 237–241, 10.1016/j.ijcard.2005.07.020.
Quintavalle C., Fiore D., De Micco F., Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury, Circulation, 2012, 126, 025, 3008–3016, 10.1161/CIRCULATIONAHA.112.128934.
Jorgensen A.L., Contrast-induced nephropathy: pathophysiology and preventive strategies, Critical Care Nurse, 2013, 33, 01, 37–46, 10.4037/ccn2013782.
Kunadian V., Zaman A., Spyridopoulos I., Qiu W., Sodium bicarbonate for the prevention of contrast induced nephropathy: a meta-analysis of published clinical trials, European Journal of Radiology, 2011, 79, 01, 48–55, 10.1016/j.ejrad.2010.02.014.
Mehran R., Nikolsky E., Contrast-induced nephropathy: definition, epidemiology, and patients at risk, Kidney International Supplements, 2006, 100, 10.1038/sj.ki.5000368.
Morcos S.K., Thomsen H.S., Webb J.A., Contrast-media-induced nephrotoxicity: a consensus report, European Radiology, 1999, 9, 08, 1602–1613, 10.1007/s003300050897.
Murphy S.W., Barrett J., Parfrey P.S., Contrast nephropathy, Journal of the American Society of Nephrology, 2000, 11, 01, 177–182, 10.1681/ASN.V111177.
Jaipaul N., Manalo R., Sadjadi S.A., Obesity is not associated with contrast nephropathy, Journal of Therapeutic Clinical Risk Management, 2010, 6, 213–217, 10.2147/TCRM.S9088.
Markota D., Markota I., Starcevic B., Prevention of contrast-induced nephropathy with Na/K citrate, European Heart Journal, 2013, 34, 030, 2362–2367, 10.1093/eurheartj/eht187.
Gulel O., Keles T., Eraslan H., Prophylactic acetylcysteine usage for prevention of contrast nephropa- thy after coronary angiography, Journal of Cardiovascular Pharmacology, 2014, 46, 04, 464–467, 10.1097/00005344-201404000-00025.
Drager L.F., Barros de Toledo J.F., Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury, Nephrology Dialysis Transplantation, 2004, 19, 07, 1803–1807, 10.1093/ndt/gfh259
Krusova D., Sevela K., Kralova D., Risky medication and contrast media-induced nephropa- thy in patients with diabetes and hypertension, Vnitrni Lekarstvi, 2014, 52, 011, 1014–1020, 10.36246/01.9201.1277995720.
Tepel M., Aspelin P., Lameire N., Contrast-induced nephropathy: a clinical and evidence-based approach, Circulation, 2006, 113, 014, 1799–1806, 10.1161/CIRCULATIONAHA.105.593210.
Teplan V., Contrast nephropathy and prevention, Vnitr Lek, 2012, 58, 07-8, 553–556.
Oguzhan N., Cilan H., Sipahioglu M., The Lack of Benefit of a Combination of an Angiotensin Receptor Blocker and Calcium Channel Blocker on Contrast-Induced Nephropathy in Patients with Chronic Kidney Disease, Ren Fail, 2013, 35, 04, 434–439, 10.3109/0886022X.2013.775643.
Gare M., Haviv Y.S., Ben A.Yehuda., The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography, J Am Coll Cardiol, 1999, 34, 06, 1682–1688, 10.1016/S0735-1097(99)00404-5.
Mamoulakis C., Tsarouhas K., Fragkiadoulaki I., Contrast-induced nephropathy: Basic concepts, pathophysiological implications, and prevention strategies, Pharmacol Ther, 2017, 180, 99–112, 10.1016/j.pharmthera.2017.06.009.
Copyright (c) 2024 Nodir U. Zakirov, Jamshid B. Irirov, Xusnidin Sh. Kuchkarov, Axtam A. Tolibov.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.